Juno Therapeutics, Inc.
Juno Therapeutics, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States, with significant operations across various regions. Founded in 2013, the company has rapidly established itself as a leader in the development of innovative cell therapies, particularly in the field of oncology. Juno is renowned for its pioneering work in CAR T-cell therapy, which harnesses the body’s immune system to target and eliminate cancer cells. This unique approach has led to groundbreaking treatments that have transformed patient outcomes in certain blood cancers. With a strong market position, Juno Therapeutics has achieved notable milestones, including successful clinical trials and partnerships that enhance its research capabilities. The company continues to push the boundaries of cancer treatment, striving to deliver life-changing therapies to patients worldwide.
DitchCarbon Score
How does Juno Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Juno Therapeutics, Inc.'s score of 26 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Juno Therapeutics, Inc.'s reported carbon emissions
In 2023, Juno Therapeutics, Inc. reported total carbon emissions of approximately 4,971,460 kg CO2e, with Scope 1 emissions at about 88,400 kg CO2e and Scope 2 emissions at approximately 4,883,060 kg CO2e. This marks a continued reduction from 2022, where total emissions were about 5,205,130 kg CO2e, with Scope 1 at approximately 99,320 kg CO2e and Scope 2 at about 5,105,810 kg CO2e. The company has demonstrated a commitment to reducing its carbon footprint, achieving a decrease in total emissions from 5,489,860 kg CO2e in 2021 to the latest figure in 2023. Despite these reductions, Juno Therapeutics has not publicly disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The company continues to focus on its operational emissions, primarily within Scope 1 and Scope 2, while the absence of Scope 3 emissions data suggests a potential area for future reporting and improvement.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Get Started| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 178,520 | 00,000 | 00,000 |
| Scope 2 | 5,311,340 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Juno Therapeutics, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
